Celcuity Inc. (NASDAQ:CELC) Receives $30.80 Consensus Target Price from Analysts

Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have received a consensus recommendation of "Buy" from the six analysts that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $30.80.

A number of brokerages have commented on CELC. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Celcuity in a report on Monday, May 19th. Needham & Company LLC reissued a "buy" rating and set a $29.00 price objective on shares of Celcuity in a report on Thursday, May 15th.

Celcuity Price Performance

Celcuity stock traded down $0.31 during trading hours on Monday, hitting $10.44. 144,757 shares of the stock were exchanged, compared to its average volume of 299,449. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock has a market capitalization of $395.32 million, a P/E ratio of -4.00 and a beta of 0.56. Celcuity has a 12 month low of $7.58 and a 12 month high of $19.77. The business's 50-day moving average is $10.19 and its two-hundred day moving average is $11.50.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09. Equities research analysts expect that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CELC. SG Americas Securities LLC boosted its stake in shares of Celcuity by 83.2% in the 4th quarter. SG Americas Securities LLC now owns 14,646 shares of the company's stock valued at $192,000 after purchasing an additional 6,651 shares during the last quarter. Bleakley Financial Group LLC bought a new position in shares of Celcuity in the 4th quarter valued at about $146,000. Rhumbline Advisers boosted its stake in shares of Celcuity by 20.6% in the 4th quarter. Rhumbline Advisers now owns 38,755 shares of the company's stock valued at $507,000 after purchasing an additional 6,625 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Celcuity by 14.9% in the 4th quarter. New York State Common Retirement Fund now owns 28,391 shares of the company's stock valued at $372,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Celcuity by 20.3% in the 4th quarter. Bank of New York Mellon Corp now owns 64,125 shares of the company's stock valued at $839,000 after purchasing an additional 10,828 shares during the last quarter. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.